Source: Securities Star
Credit Suisse issued a research report saying that it maintained the “outperform” rating of Junshi Bio (01877.HK), and lowered its 2022 and 23 earnings per share estimates by 235% and 895% based on the reduction in revenue forecast and the increase in operating costs. As there are still uncertainties in the recent launch of PD-1 in the Chinese market, the total revenue in 2022-23 will be lowered by 52% and 44%. However, thanks to the previously completed production line, the company’s long-term revenue growth is expected to increase in the next few years. , the target price was raised from HK$60 to HK$65.
Company Profile of Junshi Bio (01877.HK): Shanghai Junshi Biotechnology Co., Ltd. is a Chinese company mainly engaged in innovation-driven biopharmaceutical business. The company’s main business is the discovery, clinical research and development of innovative drugs. The company’s main products include teriprozumab injection, etevizumab, adalimumab injection, etc. for the treatment of malignant tumors, autoimmune system diseases, chronic metabolic diseases, neurological diseases and infectious diseases Drug. The company is also engaged in the clinical research and development of drugs such as recombinant humanized anti-PCSK9 monoclonal antibody injection. The company mainly provides products for domestic and foreign markets.
The above content is organized by Securities Star based on public information. If you have any questions, please contact us.Return to Sohu, see more
Editor:
Statement: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.